Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales

By sjmartinez • June 5, 2024

Kang AY, Elkomos M, Pham D, Guerrero M, Kupferwasser D, Miller LG. Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales. Antimicrob Steward Healthc Epidemiol. 2024 Jun 4;4(1):e100. doi: 10.1017/ash.2024.88. PMID: 38836043; PMCID: PMC11149041.

Tags: Harbor UCLA, Infectious Diseases, Publications

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani[...]

Shared decision making and decision aids in the management of kidney disease and renal replacement treatment options

Zisman-Ilani Y, Rhee CM, Ammary FA, Kalantar-Zadeh K. Shared decision making and decision aids in the management of kidney disease and renal replacement treatment options.[...]